Mr NEUMANN (Blair—Parliamentary Secretary for Health and Ageing and Parliamentary Secretary to the Attorney-General) (13:15): I seek leave to make an amendment to this private members' motion. Leave granted. Mr NEUMANN: I move: That the motion be amended to read— "That this House: (1) notes the concerns of key stakeholders in relation to the price reduction of chemotherapy drug Docetaxel and its potential broader impact on the treatment of cancer patients; (2) notes that the Government: (a) has announced a review into arrangements for funding chemotherapy services; (b) is providing $29.7 million in the 2013-14 Budget to pay providers an additional $60 for each chemotherapy infusion on an interim basis for six months, to cover the review period between 1 July 2013 and 31 December 2013, in addition to current fees of $76.37; and (c) demonstrated it was committed to providing drugs for cancer patients, having added 30 new drugs to treat 15 different cancers at an additional cost of $1.3 billion to the Pharmaceutical Benefits Scheme since 2007; and (3) welcomes the policy of Accelerated and Expanded Price Disclosure of items on the Pharmaceutical Benefits Scheme" Mr Pyne: Madam Deputy Speaker, I bring your attention to the state of the House. (Quorum formed) The DEPUTY SPEAKER ( Ms Hall ): The immediate question is that the amendment be agreed to. A division having been called and the bells having been rung— The SPEAKER: The division has been called off with the agreement of the Leader of the House and the Manager of Opposition Business. The Leader of the House has the call.